Our news section contains recent news on neuroendocrine tumors, upcoming NANETS events and information, and people in our community. Have a suggestion? Please click here to contact us.

2017 Basic Translational Science Investigator

NANETS congratulates Brian Untch, MD of Memorial Sloan Kettering Cancer Center as the NANETS 2017 Basic Translational Science In

2017 NANETS Clinical Investigator Scholarship

NANETS congratulates Etay Ziv, MD, PhD of Memorial Sloan Kettering Cancer Center as the 2017 NANETS Clinical Investigator Scholarship recipient.  The NCIS award focuses on supporting a clinical project as well as the investigator's potential to make future clinical contributions to the neuroendo

Novartis Announces the Planned Acquisition of Advanced Accelerator Applications

Novartis announced that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Advanced Accelerator Applications (NASDAQ:AAAP) is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera® (177Lu-DOTATATE), a first-in-class RLT product for neuroendocrine tumors (NETs). Radiopharmaceuticals, such as Lutathera, are unique medicinal formulations containing radioisotopes which are used clinically for both diagnosis and therapy. The transaction would strengthen Novartis' oncology presence with both near-term product launches as well as a new technology platform with potential applications across a number of oncology early development programs.

NANETS2017 Registration Update

Dear NANETS Members and Colleagues,

We are so grateful to everyone interested in attending the 10th Annual NANETS Symposium, October 19-21, 2017 in Philadelphia, PA. We have exceeded last year by over 180 registrants

For the first time ever, the annual NANETS Symposium has SOLD OUT. Due to hotel capacity rules and fire codes we unfortunately cannot accommodate any more registrants, including any walk-up registrations.

NANETS to Present Basic/Translational Science Investigator Award

The North American Neuroendocrine Tumor Society (NANETS) is pleased to announce the Neuroendocrine Tumor Research Foundation (NETRF) Board of Directors has approved funding for the Basic/Translational Science Investigator (BTSI) Award for 2017 presented by NANETS. The 2017 award will be announced at the NANETS 10th annual symposium, to be held October 19-21 in Philadelphia, PA.

NANETS to Present Clinical Investigator Scholarship

The North American Neuroendocrine Tumor Society (NANETS) will present the NANETS Clinical Investigator Scholarship at the organization’s 10th annual symposium, to be held October 19-21 in Philadelphia, PA.

NET Funding Opportunity: Neuroendocrine Tumor Specialized Program of Research Excellence (SPORE)

NANETS member M. Sue O’Dorisio, MD, PhD, of the University of Iowa Hospitals & Clinics, seeks applicants for two Developmental Research Program awards ($50,000 each) and one Career Enhancement Program award ($100,000). The deadline to apply is Monday, July 17, 2017.

NANETS Announces Symposium Keynote

Drew Pardoll, MD, PhD, of Johns Hopkins Medical Institutions, will be presenting the keynote on Friday, October 20 at the 2017 symposium in Philadelphia, Pennsylvania. His topic will be "Harnessing the Patient’s Immune System Against Their Tumor: The Revolution in Cancer Therapy." He observed that the application of 40 years of basic immunology and cancer immunology is now paying off in the establishment of immunotherapy as a new pillar of cancer treatment.

NANETS2017 Early Bird Registration - Open Now!

The North American Neuroendocrine Tumor Society (NANETS) invites you to attend our 10th Annual Symposium. Join us in Philadelphia, Pennsylvania, USA, on October 19-21, 2017 for the premier gathering of medical professionals involved in the study and treatment of neuroendocrine tumor (NET) disease.

Pages